Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 48

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 48
---
 We do, however, pay the premiums for term life insurance and disability insurance for all of our employees, including our named executive officers.

#### Tax and Accounting Implications
Under Financial Accounting Standard Board (“ FASB ”) ASC Topic 718 (“ ASC 718 ”), we are required to estimate and record an expense for each award of equity compensation over the vesting period of the award. We record share-based compensation expense on an ongoing basis according to ASC 718.

Under Section 162(m) of the Code, compensation paid to each of our “covered employees” that exceeds $1 million per taxable year is generally non-deductible. Although our Compensation Committee will continue to consider tax implications as one factor in determining executive compensation, our Compensation Committee also looks at other factors in making its decisions and retains the flexibility to provide compensation for our executive officers, including our named executive officers, in a manner consistent with the goals of our executive compensation program and the best interests of the Company and its stockholders, which may include providing for compensation that is not deductible by us.

#### Equity-Related Policies

#### Clawback Policy
As a public company, if we are required to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws as a result of misconduct, the Chief Executive Officer and Chief Financial Officer may be legally required to reimburse our Company for any bonus or other incentive-based or equity-based compensation they receive in accordance with the provisions of section 304 of the Sarbanes Oxley Act of 2002, as amended. Additionally, we have implemented a Dodd-Frank Act-compliant clawback policy, as required by SEC rules.

#### Equity Grant Policies
Stock options are currently granted to our named executive officers under our 2019 Plan. Executives’ stock options are granted with an exercise price based on the fair market value, which is established by the 2019 Plan and generally is the closing price of our common stock on the date of grant or, if there is no such closing price, the closing price on the last preceding date for which there is a closing price. For a further discussion, please see the section titled “Executive Compensation—Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information.”

#### Hedging and Pledging Policy
Our named executive officers are prohibited from engaging in speculative transactions with respect to our capital stock, and they are also prohibited from pledging any of our capital stock as security.